GO:2000491 positive regulation of hepatic stellate cell activation: Fibrosis Driver, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000491 describes any process that activates or increases the frequency, rate or extent of hepatic stellate cell activation, the central event in liver fibrosis.
• Hepatic stellate cells (HSCs) transition from quiescent vitamin A-storing cells to proliferative, contractile, extracellular matrix-producing myofibroblasts during activation.
• Multiple signaling axes positively regulate HSC activation, including HIF-1α/SLC7A11, succinate-GPR91, JCAD, MERTK, and endothelial GATA4-dependent angiocrine signals.
• Positive regulation of HSC activation is a driver of MASH (metabolic dysfunction-associated steatohepatitis), cholestatic fibrosis, and hepatocellular carcinoma progression.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal dissection of genes that positively regulate HSC activation.
• Targeting positive regulators of HSC activation, such as MERTK or succinate-GPR91 signaling, reduces fibrosis in preclinical models, highlighting therapeutic potential.
Description
GO:2000491, positive regulation of hepatic stellate cell activation, is a Gene Ontology biological process term that captures any molecular event that activates or increases the frequency, rate, or extent of hepatic stellate cell (HSC) activation. HSC activation is the pivotal cellular transition in liver fibrogenesis, in which quiescent, vitamin A-storing HSCs transdifferentiate into proliferative, contractile, and extracellular matrix (ECM)-producing myofibroblasts. Because this process is a shared endpoint of chronic liver injury from metabolic, cholestatic, viral, and toxic etiologies, understanding its positive regulators is central to fibrosis research. Mechanistically, positive regulation of HSC activation is driven by a network of paracrine and autocrine signals. Endothelial GATA4 loss promotes a pathogenic switch in angiocrine signaling that activates HSCs and impairs liver regeneration. Metabolic stress and macrophage-derived signals, such as METTL14-dependent S100A4+ monocyte-derived macrophages acting through MyD88/NF-κB, further amplify the pro-fibrotic microenvironment. In MASH, decreased LONP1 expression elevates orotic acid levels and exacerbates fibrosis, illustrating how metabolic rewiring can positively regulate HSC activation. For researchers, GO:2000491 provides a structured framework to annotate and interrogate the upstream inputs that drive HSC activation. Key positive regulators include HIF-1α/SLC7A11-dependent ferroptosis resistance, succinate-GPR91 signaling, JCAD, MERTK, and Sema3C-mediated stromal remodeling. These pathways are experimentally tractable using CRISPR knockout, point mutation, knock-in, and overexpression models, making GO:2000491 a high-value target for mechanistic and therapeutic studies.
positive regulation of hepatic stellate cell activation At A Glance
| GO ID | GO:2000491 |
|---|---|
| GO term | positive regulation of hepatic stellate cell activation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Activates or increases the frequency, rate, or extent of hepatic stellate cell activation, driving liver fibrogenesis |
| Key upstream signals | HIF-1α/SLC7A11, succinate-GPR91, JCAD, MERTK, endothelial GATA4-dependent angiocrine signaling |
| Associated diseases | MASH, cholestatic fibrosis, hepatocellular carcinoma |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, RNA-seq, proteomics, imaging |
What Is GO:2000491?
According to the QuickGO definition, GO:2000491 (positive regulation of hepatic stellate cell activation) refers to any process that activates or increases the frequency, rate, or extent of hepatic stellate cell activation. In practical terms, it encompasses all molecular and cellular events that promote the transition of quiescent HSCs into activated myofibroblast-like cells, including increased proliferation, contractility, ECM production, and pro-inflammatory cytokine secretion.
Why Is positive regulation of hepatic stellate cell activation Important in Cell Biology?
Positive regulation of hepatic stellate cell activation is important because HSC activation is the central driver of liver fibrosis across diverse chronic liver diseases, and identifying the positive regulators of this process offers direct therapeutic targets. For example, blocking succinate-GPR91 signaling in HSCs suppresses MASH fibrotic progression, and MERTK inhibition reduces organ fibrosis in mouse models. Similarly, targeting HIF-1α/SLC7A11-dependent pathways attenuates liver fibrosis by triggering HSC ferroptosis. Understanding GO:2000491 therefore bridges mechanistic cell biology and translational antifibrotic drug discovery.
• HSC activation is the final common pathway of liver fibrosis, making its positive regulators high-priority therapeutic targets.
• Positive regulation of HSC activation contributes to MASH progression and metabolic liver disease.
• It drives cholestatic fibrosis, as shown by JCAD deficiency attenuating HSC activation and cholestatic fibrosis.
• It promotes hepatocellular carcinoma progression through stromal remodeling, e.g., Sema3C.
• Endothelial GATA4 loss causes a pathogenic angiocrine switch that positively regulates HSC activation and impairs regeneration.
• MERTK inhibition reduces organ fibrosis, demonstrating druggability of positive regulators.
• Succinate-GPR91 signaling in HSCs is a targetable positive regulator of MASH fibrosis.
• Ferroptosis resistance via HIF-1α/SLC7A11 sustains activated HSCs and fibrosis.
• Macrophage-derived signals, such as METTL14-dependent S100A4+ monocytes via MyD88/NF-κB, amplify HSC activation.
• CRISPR models enable causal validation of candidate positive regulators for antifibrotic discovery.
What Happens During positive regulation of hepatic stellate cell activation?
Initiation: Paracrine and Metabolic Triggers
In simple terms: Injury signals from other liver cells and metabolic stress start the process.
Positive regulation of HSC activation begins when chronic liver injury triggers paracrine signals from endothelial cells, macrophages, and hepatocytes. Endothelial GATA4 loss causes a pathogenic switch in angiocrine signaling that activates HSCs and impairs liver regeneration. Metabolic stress in MASH, such as decreased LONP1 expression and elevated orotic acid, exacerbates fibrosis and promotes HSC activation. Macrophage-derived signals, including METTL14-downregulated S100A4+ monocyte-derived macrophages acting via MyD88/NF-κB, further drive the pro-fibrotic microenvironment.
Amplification: Succinate-GPR91 and HIF-1α/SLC7A11 Signaling
In simple terms: Specific molecular pathways amplify the activation signal inside and around HSCs.
Once initiated, positive regulation is amplified by dedicated signaling axes. Succinate-GPR91 signaling in HSCs promotes MASH fibrotic progression, and blocking this pathway suppresses fibrosis. HIF-1α/SLC7A11 signaling sustains HSC survival by resisting ferroptosis; sorafenib attenuates liver fibrosis by triggering HSC ferroptosis via this pathway. These amplification loops reinforce the activated phenotype and ECM production.
Effector Phase: JCAD, MERTK, and Sema3C
In simple terms: Effector proteins execute and sustain the activated state.
The effector phase of positive regulation involves proteins such as JCAD, MERTK, and Sema3C. JCAD deficiency attenuates HSC activation and cholestatic fibrosis, indicating JCAD positively regulates this process. MERTK inhibition reduces organ fibrosis in mouse models, showing MERTK is a positive regulator of HSC activation. Sema3C reshapes the stromal microenvironment to promote hepatocellular carcinoma progression, linking positive regulation of HSC activation to tumor stroma.
Phenotypic Outcome: Myofibroblast Transition and ECM Deposition
In simple terms: The end result is scar-forming cells that build up matrix.
The cumulative outcome of positive regulation of HSC activation is the transition of quiescent HSCs into proliferative, contractile myofibroblasts that deposit excessive extracellular matrix. This phenotypic switch is sustained by the signaling axes described above and is reversible in some models when the positive regulators are blocked, as shown by succinate-GPR91 and MERTK inhibition. The activated state also promotes angiogenesis and tumor progression through stromal remodeling.
Key Genes Involved in GO:2000491 positive regulation of hepatic stellate cell activation
The following genes and proteins have been experimentally implicated in positive regulation of hepatic stellate cell activation, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LONP1 | Mitochondrial protease; decreased expression elevates orotic acid and exacerbates MASH fibrosis | Metabolic regulator of HSC activation in MASH |
| SLC7A11 | Cystine/glutamate antiporter; mediates ferroptosis resistance downstream of HIF-1α | Target for triggering HSC ferroptosis and attenuating fibrosis |
| HIF-1α | Transcription factor upstream of SLC7A11; promotes HSC survival | Hypoxia-driven positive regulator of HSC activation |
| Sema3C | Secreted semaphorin; reshapes stromal microenvironment | Links HSC activation to HCC progression |
| GATA4 | Endothelial transcription factor; loss causes pathogenic angiocrine switch | Controls liver fibrosis and regeneration via angiocrine signals |
| JCAD | Junctional protein; deficiency attenuates HSC activation | Positive regulator in cholestatic fibrosis |
| METTL14 | RNA methyltransferase; downregulation drives S100A4+ macrophages | Epitranscriptomic regulator of MAFLD progression |
| S100A4 | Macrophage marker; monocyte-derived macrophages promote MAFLD | Immune cell mediator of HSC activation |
| MyD88 | Adaptor in NF-κB signaling; mediates macrophage-driven inflammation | Inflammatory pathway promoting HSC activation |
| NF-κB | Transcription factor downstream of MyD88; drives pro-inflammatory gene expression | Central inflammatory regulator in MAFLD |
| MERTK | Receptor tyrosine kinase; inhibition reduces organ fibrosis | Druggable positive regulator of HSC activation |
| GPR91 | Succinate receptor; mediates succinate signaling in HSCs | Target for suppressing MASH fibrotic progression |
| SUCNR1 | Alternative name for GPR91; succinate receptor | Metabolic signaling node in HSC activation |
| ACTA2 | Alpha-smooth muscle actin; marker of activated HSCs | Readout of HSC activation in experiments |
| COL1A1 | Type I collagen; major ECM component produced by activated HSCs | Fibrosis marker and functional output |
| TGF-β | Profibrotic cytokine; classic positive regulator of HSC activation | Benchmark pathway for comparison |
| PDGFRβ | Receptor for PDGF; promotes HSC proliferation | Target for antiproliferative strategies |
| YAP/TAZ | Mechanotransduction effectors; promote myofibroblast transition | Mechanistic node in HSC activation |
How Is positive regulation of hepatic stellate cell activation Regulated?
Positive regulation of hepatic stellate cell activation is itself regulated by multiple upstream inputs. Endothelial GATA4 acts as a gatekeeper: its loss triggers a pathogenic angiocrine switch that positively regulates HSC activation. Metabolic signals, including succinate via GPR91 and orotic acid downstream of LONP1 loss, directly promote HSC activation. Inflammatory signaling through MyD88/NF-κB in S100A4+ macrophages amplifies the pro-fibrotic milieu. Hypoxia and HIF-1α signaling sustain HSC survival by upregulating SLC7A11 and resisting ferroptosis. These regulatory layers provide multiple entry points for therapeutic intervention.
positive regulation of hepatic stellate cell activation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LONP1 | MASH-induced liver fibrosis | Lonp1 knockout or knockdown in HSCs; MASH diet mouse model |
| SLC7A11 | Liver fibrosis via ferroptosis resistance | Slc7a11 knockout or overexpression in HSCs; sorafenib treatment |
| JCAD | Cholestatic fibrosis | Jcad knockout mouse; bile duct ligation model |
| MERTK | Organ fibrosis | Mertk knockout or inhibitor-treated mouse models |
| GPR91 | MASH fibrotic progression | Gpr91 knockout mouse; succinate challenge |
MASH and Metabolic Liver Disease
Positive regulation of HSC activation is a central driver of MASH fibrosis. Decreased LONP1 expression exacerbates MASH-induced liver fibrosis via elevated orotic acid levels. METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB to promote MAFLD progression. Blocking succinate-GPR91 signaling in HSCs suppresses MASH fibrotic progression, demonstrating that targeting positive regulators is therapeutically beneficial.
Cholestatic Fibrosis
JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis, identifying JCAD as a positive regulator in cholestatic liver disease. This suggests that genes annotated to GO:2000491 may be relevant across fibrotic etiologies beyond metabolic disease.
Hepatocellular Carcinoma
Sema3C reshapes the stromal microenvironment to promote hepatocellular carcinoma progression, linking positive regulation of HSC activation to tumor stroma and cancer progression. Endothelial GATA4-dependent angiocrine signaling also controls liver fibrosis and regeneration, with implications for HCC development.
Organ Fibrosis Beyond the Liver
MERTK inhibition reduces organ fibrosis in mouse models of fibrotic disease, indicating that positive regulation of HSC activation shares mechanisms with fibrosis in other organs. This broadens the therapeutic relevance of GO:2000491 beyond liver-specific contexts.
From positive regulation of hepatic stellate cell activation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is LONP1 causally involved in MASH fibrosis? | Lonp1 knockout or knockdown in HSCs; MASH diet mouse |
| Does SLC7A11 mediate ferroptosis resistance in HSCs? | Slc7a11 knockout or overexpression; sorafenib treatment |
| Does JCAD positively regulate HSC activation? | Jcad knockout mouse; cholestatic fibrosis model |
| Can MERTK inhibition reduce fibrosis? | Mertk knockout or small-molecule inhibitor in mouse fibrosis models |
| Does succinate-GPR91 signaling drive MASH fibrosis? | Gpr91 knockout mouse; succinate infusion |
| Does endothelial GATA4 loss promote HSC activation? | Endothelial-specific Gata4 knockout mouse |
How to Study the positive regulation of hepatic stellate cell activation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptome changes during HSC activation | Identify positive regulators and activation signatures |
| Proteomics | Protein abundance and modifications | Discover metabolic regulators like LONP1 |
| Metabolomics | Metabolite levels such as succinate and orotic acid | Link metabolism to HSC activation |
| Immunofluorescence | ACTA2 and COL1A1 expression in tissue | Validate HSC activation in situ |
| Ferroptosis assay | Lipid peroxidation and cell viability | Assess HIF-1α/SLC7A11 pathway |
| Primary HSC culture | Proliferation, migration, contractility | Functional testing of candidate genes |
| Macrophage co-culture | Inflammatory signaling to HSCs | Model immune-stromal interactions |
| Mouse fibrosis models | Liver fibrosis and regeneration in vivo | Preclinical validation of targets |
Transcriptomic and Epitranscriptomic Profiling
RNA-seq and epitranscriptomic profiling can identify genes and pathways that positively regulate HSC activation. For example, METTL14 downregulation was linked to S100A4+ macrophage-driven MAFLD progression using such approaches. Comparing quiescent versus activated HSCs by RNA-seq reveals activation signatures including ACTA2 and COL1A1.
Proteomic and Metabolomic Analysis
Proteomics and metabolomics uncover metabolic regulators of HSC activation. Decreased LONP1 expression was shown to elevate orotic acid levels, linking mitochondrial proteostasis to fibrosis. Succinate-GPR91 signaling was identified through metabolic profiling of MASH models.
Imaging and Histology
Immunofluorescence and immunohistochemistry for alpha-smooth muscle actin (ACTA2) and collagen I (COL1A1) are standard readouts of HSC activation in tissue sections. These methods validate whether a candidate gene positively regulates HSC activation in vivo.
Functional Assays in HSC Cultures
Primary HSC isolation and culture, followed by proliferation, migration, and contractility assays, directly measure positive regulation of HSC activation. Ferroptosis assays, such as lipid peroxidation and viability measurements, assess HIF-1α/SLC7A11-dependent survival.
How CRISPR Can Be Used to Study GO:2000491 positive regulation of hepatic stellate cell activation
Knockout
CRISPR knockout of candidate positive regulators such as JCAD, MERTK, or GPR91 in HSCs or mouse models can test whether loss of function attenuates HSC activation and fibrosis. For example, Jcad deficiency attenuates HSC activation and cholestatic fibrosis, and Mertk inhibition reduces organ fibrosis.
Point Mutation
CRISPR point mutation can dissect specific residues or domains required for positive regulation of HSC activation. For instance, mutating catalytic or binding residues in MERTK or GPR91 could separate signaling functions from scaffolding roles. Such models help validate mechanism-of-action for drug targets.
Knock-in
Knock-in of reporters or tags, such as ACTA2-driven fluorescent reporters or epitope-tagged SLC7A11, enables tracking of HSC activation in real time. Knock-in of disease-associated variants can model genetic contributions to fibrosis susceptibility.
Overexpression
CRISPR overexpression of candidate genes such as Sema3C or SLC7A11 can test sufficiency for promoting HSC activation and fibrosis. Overexpression models complement knockout studies to establish bidirectional causality.
How EDITGENE Supports positive regulation of hepatic stellate cell activation Research
Researchers studying positive regulation of hepatic stellate cell activation-related genes often need to determine whether a candidate gene is causally involved in driving HSC activation or is merely a bystander. Rigorous causal inference requires loss-of-function and gain-of-function models in relevant cell types and in vivo systems, paired with quantitative readouts of HSC activation such as ACTA2 and COL1A1 expression. EDITGENE provides end-to-end CRISPR services to build these models efficiently.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of hepatic stellate cell activation research.
Frequently Asked Questions About positive regulation of hepatic stellate cell activation
What is GO:2000491 positive regulation of hepatic stellate cell activation?
GO:2000491 is a Gene Ontology biological process term defined as any process that activates or increases the frequency, rate, or extent of hepatic stellate cell activation, the central event in liver fibrosis.
What genes are involved in positive regulation of hepatic stellate cell activation?
Key genes include LONP1, SLC7A11, HIF-1α, Sema3C, GATA4, JCAD, METTL14, S100A4, MyD88, NF-κB, MERTK, and GPR91, based on published studies.
How is hepatic stellate cell activation positively regulated?
It is positively regulated by paracrine signals such as endothelial GATA4-dependent angiocrine signaling, metabolic signals like succinate-GPR91 and orotic acid, inflammatory signals via MyD88/NF-κB, and survival signals through HIF-1α/SLC7A11.
Why is positive regulation of hepatic stellate cell activation important in disease?
It drives liver fibrosis in MASH, cholestatic disease, and contributes to hepatocellular carcinoma progression, making it a key therapeutic target.
What experimental models study positive regulation of hepatic stellate cell activation?
Common models include primary HSC cultures, knockout mice for genes like Jcad, Mertk, and Gpr91, and MASH or cholestatic fibrosis models.
Can CRISPR be used to study positive regulation of hepatic stellate cell activation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of candidate genes in HSC activation.
What is the role of MERTK in hepatic stellate cell activation?
MERTK is a receptor tyrosine kinase whose inhibition reduces organ fibrosis in mouse models, indicating it positively regulates HSC activation.
How does succinate-GPR91 signaling affect HSC activation?
Succinate-GPR91 signaling in HSCs promotes MASH fibrotic progression, and blocking this pathway suppresses fibrosis.
What markers indicate hepatic stellate cell activation?
ACTA2 (alpha-smooth muscle actin) and COL1A1 (type I collagen) are standard markers of activated HSCs.
What is the relationship between ferroptosis and HSC activation?
HIF-1α/SLC7A11 signaling confers ferroptosis resistance in HSCs; triggering ferroptosis via this pathway attenuates liver fibrosis.
Conclusion
GO:2000491 positive regulation of hepatic stellate cell activation is a central biological process in liver fibrosis, integrating metabolic, inflammatory, endothelial, and survival signals that drive HSC transition to myofibroblasts. The verified literature identifies multiple positive regulators, including LONP1, SLC7A11, JCAD, MERTK, and GPR91, whose inhibition reduces fibrosis in preclinical models. For researchers, CRISPR-based knockout, point mutation, knock-in, and overexpression models provide the causal tools needed to validate candidate genes within this GO term. EDITGENE offers comprehensive services to accelerate discovery of antifibrotic targets and biomarkers related to positive regulation of hepatic stellate cell activation.
References
- 1. Xu D et al.. 2026. Decreased LONP1 expression exacerbates MASH-induced liver fibrosis via elevated orotic acid levels.. J Hepatol 84(1):165-180 PMID: 40784490
- 2. Yuan S et al.. 2022. Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1α/SLC7A11 pathway.. Cell Prolif 55(1):e13158 PMID: 34811833
- 3. Peng H et al.. 2024. Semaphorin 3C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression.. Signal Transduct Target Ther 9(1):169 PMID: 38956074
- 4. Winkler M et al.. 2021. Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling.. J Hepatol 74(2):380-393 PMID: 32916216
- 5. Xie L et al.. 2024. JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis.. Clin Mol Hepatol 30(2):206-224 PMID: 38190829
- 6. Wang YF et al.. 2024. METTL14 downregulation drives S100A4(+) monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression.. Signal Transduct Target Ther 9(1):91 PMID: 38627387
- 7. Pan Z et al.. 2024. Inhibition of MERTK reduces organ fibrosis in mouse models of fibrotic disease.. Sci Transl Med 16(741):eadj0133 PMID: 38569018
- 8. Xie L et al.. 2026. Suppressing MASH fibrotic progression by blocking succinate-GPR91 signaling in HSCs.. Hepatology 83(4):888-906 PMID: 40392081
